Clinical Trials Browser

Leukemia, Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT06626256 2025-12-24

STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma

Phase 1 Withdrawn

DermatologicGastrointestinalGenitourinaryGynecologic

Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms, Colorectal Neoplasms

NCT02548468 2025-05-02

Reduced Intensity Conditioning Before Partially Matched Donor Stem Cell Transplant in Treating Patients With Advanced Cutaneous T Cell Lymphoma

Phase 1 Withdrawn

DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT06094842 2025-04-01

Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer

Phase 1 Withdrawn

Genitourinary

Prostatic Neoplasms

NCT06341647 2025-01-24

Phase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201

Phase 1 Withdrawn

BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms

NCT06003179 2024-11-12

LOKI

Phase 1 Withdrawn

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT05950113 2024-05-01

CART-BCMA/CS1 in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase 1 Withdrawn

Plasma cell

Multiple Myeloma

NCT05934097 2023-07-06

FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma

Phase 1 Withdrawn

Lymphoid

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT05513612 2023-03-01

Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies

Phase 1 Withdrawn

LymphoidOther hematologic neoplasmPlasma cell

Burkitt Lymphoma, Multiple Myeloma, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT05531708 2023-03-01

Exploratory Study of Novel MSLN CAR-T Cell Therapy in Patients With MSLN-positive Advanced Refractory Solid Tumors

Phase 1 Withdrawn

Other solid neoplasm

Mesothelin-positive Advanced Refractory Solid Tumors

NCT04974996 2022-03-29

LOTIS-8

Phase 1 Withdrawn

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT03773744 2021-04-06

Pelican

Phase 1 Withdrawn

Dermatologic

Melanoma

NCT00004114 2020-07-31

Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Hematologic Cancer

Phase 1 Withdrawn

DermatologicLymphoidMyeloidOther hematologic neoplasm

Burkitt Lymphoma, Hodgkin Disease, Leukemia, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Mycosis Fungoides, Myelodysplastic Syndromes, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT04093648 2020-05-20

T Cells co- Expressing a Second Generation Glypican 3-specific Chimeric Antigen Receptor With Cytokines Interleukin-21 and 15 as Immunotherapy for Patients With Liver Cancer (TEGAR)

Phase 1 Withdrawn

Gastrointestinal

Carcinoma, Hepatocellular, Hepatoblastoma

NCT02274506 2020-01-22

Infusion of Allogeneic, 3rd Party CD19-specific T Cells

Phase 1 Withdrawn

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03575234 2019-08-28

Nivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or HPV-Positive Oropharyngeal Cancer

Phase 1 Withdrawn

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT02863913 2019-03-06

PD-1 Knockout Engineered T Cells for Muscle-invasive Bladder Cancer

Phase 1 Withdrawn

Genitourinary

Invasive Bladder Cancer Stage IV

NCT02867332 2019-03-06

PD-1 Knockout Engineered T Cells for Metastatic Renal Cell Carcinoma.

Phase 1 Withdrawn

Genitourinary

Carcinoma, Renal Cell

NCT03531281 2018-12-07

Human Lysozyme Goat Milk in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant

Phase 1 Withdrawn

Other hematologic neoplasm

Hematologic Neoplasms

NCT03285607 2018-08-16

MCS110 Combined With Neoadjuvant Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast Cancer

Phase 1 Withdrawn

Breast

Breast Neoplasms

NCT02489266 2017-07-27

In Vivo Persistence of Adoptively-Transferred TIL Cultured With Akti in People With Metastatic Melanoma

Phase 1 Withdrawn

Dermatologic

Melanoma

NCT02210104 2017-07-21

Adoptive Therapy Using Antigen-Specific CD4 T-Cells

Phase 1 Withdrawn

DermatologicSarcoma

Melanoma, Neoplasm Metastasis, Sarcoma

NCT02439788 2017-06-14

GINAKIT

Phase 1 Withdrawn

CNS

Neuroblastoma

NCT02194374 2017-06-12

Autologous ROR1R-CAR-T Cells for Chronic Lymphocytic Leukemia (CLL)

Phase 1 Withdrawn

LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02595242 2017-05-23

Safety and Efficacy Study of CNOP Chemotherapy in Diffuse Large B Cell Lymphoma

Phase 1 Withdrawn

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT01731587 2017-02-28

FINGERPRINT

Phase 1 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02059850 2016-02-03

NY-ESO-1 Specific T Cells After Cyclophosphamide in Treating Patients With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

Phase 1 Withdrawn

Sarcoma

Sarcoma, Sarcoma, Synovial, Liposarcoma, Myxoid

NCT00006126 2015-11-13

Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Small Cell Lung, Breast, Testicular, or Kidney Cancer That is Metastatic or That Cannot Be Treated With Surgery

Phase 1 Withdrawn

BreastDermatologicGenitourinaryThoracic

Testicular Germ Cell Tumor, Breast Neoplasms, Carcinoma, Renal Cell, Kidney Neoplasms, Lung Neoplasms, Melanoma, Testicular Neoplasms, Small Cell Lung Carcinoma

NCT00074139 2014-03-05

Docetaxel, Doxorubicin, and Cyclophosphamide in Treating Women With Advanced Breast Cancer

Phase 1 Withdrawn

Breast

Breast Neoplasms

NCT00937300 2011-11-23

T-cell Based Immunotherapy for Head and Neck Cancer

Phase 1 Withdrawn

Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms

Clinical Trials

Cryopreserved MMUD BM With PTCy for Hematologic Malignancies

STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma

Reduced Intensity Conditioning Before Partially Matched Donor Stem Cell Transplant in Treating Patients With Advanced Cutaneous T Cell Lymphoma

Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer

Phase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201

LOKI

CART-BCMA/CS1 in Treating Patients With Relapsed or Refractory Multiple Myeloma

FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma

Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies

Exploratory Study of Novel MSLN CAR-T Cell Therapy in Patients With MSLN-positive Advanced Refractory Solid Tumors

LOTIS-8

Pelican

Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Hematologic Cancer

T Cells co- Expressing a Second Generation Glypican 3-specific Chimeric Antigen Receptor With Cytokines Interleukin-21 and 15 as Immunotherapy for Patients With Liver Cancer (TEGAR)

Infusion of Allogeneic, 3rd Party CD19-specific T Cells

Nivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or HPV-Positive Oropharyngeal Cancer

PD-1 Knockout Engineered T Cells for Muscle-invasive Bladder Cancer

PD-1 Knockout Engineered T Cells for Metastatic Renal Cell Carcinoma.

Human Lysozyme Goat Milk in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant

MCS110 Combined With Neoadjuvant Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast Cancer

In Vivo Persistence of Adoptively-Transferred TIL Cultured With Akti in People With Metastatic Melanoma

Adoptive Therapy Using Antigen-Specific CD4 T-Cells

GINAKIT

Autologous ROR1R-CAR-T Cells for Chronic Lymphocytic Leukemia (CLL)

Safety and Efficacy Study of CNOP Chemotherapy in Diffuse Large B Cell Lymphoma

FINGERPRINT

NY-ESO-1 Specific T Cells After Cyclophosphamide in Treating Patients With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Small Cell Lung, Breast, Testicular, or Kidney Cancer That is Metastatic or That Cannot Be Treated With Surgery

Docetaxel, Doxorubicin, and Cyclophosphamide in Treating Women With Advanced Breast Cancer

T-cell Based Immunotherapy for Head and Neck Cancer